[3T15] Medical Inovation 02

11:10 AM - 11:20 AM JST(2:10 AM - 2:20 AM UTC)

[3T15-06] Intranasal administration of linear ubiquitin chain assembly complex (LUBAC) inhibitor ameliorates disease pathology in a mouse model of amyotrophic lateral sclerosis.

^○Yukari Hatanaka¹, Daisuke Oikawa¹, Kazuto Tsukita², Takami Tomiyama³, Yosuke Demizu^4,5,6, Yoshinosuke Usuki⁷, Fuminori Tokunaga^1,8 (1.Dept. of Med. Biochem., Grad. Sch. of Med., Osaka Metropol. Univ., 2.Dept. of Neurol., Grad. Sch. of Med., Kyoto Univ., 3.Dept. of Transl. Neurosci., Grad. Sch. of Med., Osaka Metropol. Univ., 4.Div. of Org. Chem., Nat. Inst. of Health Sci., 5.Grad. Sch. of Med. Life Sci., Yokohama City Univ., 6.Grad. Sch. of Med., Dentist. and Pharm. Sci., Div. of Pharm. Sci. of Okayama Univ., 7.Dept. of Chem., Grad. Sch. of Sci., Osaka Metropol. Univ., 8.Res. Inst. for Drug Discov. Sci., Osaka Metropol. Univ.)

キーテクノロジー：経鼻投与

Keywords:

ALS,直鎖状ユビキチン鎖,ユビキチンリガーゼ阻害剤,TDP-43,ユビキチン陽性封入体

Password required to view